Posted On: May 15, 2026
For years, hormone replacement therapy carried a warning label that scared women away from one of the most effective treatments in menopause medicine. That label has now changed and so has the conversation.
In November 2025, the FDA announced it would initiate removal of long-standing black box warnings across hormone therapy products.1 In February 2026, it approved label changes to six systemic hormone therapy products, removing warnings for cardiovascular disease, breast cancer, and dementia.2 Both actions said the same thing: warnings written for a specific older population and a specific formulation had been applied, incorrectly and too broadly, to all forms of hormone therapy for more than two decades.
The result? Millions of women undertreated, and millions more told that hormones weren’t safe when the evidence said otherwise.
Prescriptions for hormone therapy have increased 72% since 2021,3 and in some situations, supplies are selling out. Women are asking for it again, and the science supports that renewed interest. For women in the right window, hormone therapy is preventive medicine: protecting the heart, the skeleton, and the brain against changes that compound quietly over decades.
If you’ve been avoiding HRT based on something you heard years ago, here is what the current evidence actually shows.
Hormone therapy (often called HRT, or hormone replacement therapy, and also known as MHT, or menopause hormone therapy) means replacing the estrogen (and, when needed, progesterone) that your body gradually stops producing as you approach and enter menopause. For most women, that decline begins gradually in perimenopause (often starting in the late 30s or early 40s) and reaches its endpoint in the late 40s to early 50s, though it can occur earlier due to surgery or other medical reasons.
In my training and practice, hormone therapy is the most effective treatment available for moderate to severe hot flashes and night sweats. It is also first-line treatment for genitourinary symptoms of menopause (a term I’ll explain later in this post).
Most women expect menopause to arrive with hot flashes. Many are already well into the transition before they realize it. Menopause is defined as 12 consecutive months without a period. However, perimenopause, the years leading up to that point, can begin in the late 30s or early 40s and often looks quite different. Irregular or heavier periods, anxiety, depression, persistent fatigue, disrupted sleep, brain fog, and heart palpitations frequently appear long before the classic hot flashes do.
This distinction matters for hormone therapy. The cardiovascular and bone protection that estrogen provides is strongest when therapy begins during or shortly after this transition, and many women who would benefit most don’t yet realize that the changes they’re noticing are hormonal.
Not all hormone therapy is the same, and the differences matter more than most people realize.
Systemic hormone therapy enters the bloodstream and addresses symptoms throughout the body. It comes in several forms:
Route of delivery is a real clinical consideration: transdermal estrogen (patches, gels, and sprays) carries a lower risk of blood clots and stroke compared to oral estrogen, and this comes up early in every conversation I have with patients about starting hormone therapy.
If you still have a uterus, systemic estrogen is always paired with a progestogen (progesterone or a synthetic version). Estrogen alone, without progestogen protection, increases the risk of uterine cancer in women who haven’t had a hysterectomy.
Low-dose vaginal estrogen works locally, staying in the vaginal tissues without being absorbed into the bloodstream in clinically significant amounts. It’s prescribed specifically for genitourinary symptoms of menopause: vaginal dryness, painful intercourse, and urinary changes like increased urgency or recurrent urinary tract infections.
This matters because the risk profile of local vaginal estrogen is fundamentally different from systemic therapy. Some women who are not candidates for systemic hormones (including women with certain cancer histories) may still be candidates for low-dose vaginal estrogen. That conversation is worth having with your physician if you’ve been told hormones are off the table entirely.
Testosterone sometimes enters the conversation for women who are already on estrogen therapy and continue to experience low libido or sexual dysfunction. It is most often considered an addition to an existing hormone regimen, typically when estrogen therapy alone has not fully addressed those symptoms. It is not FDA-approved for women in the United States, but some physicians prescribe it off-label when there is a clear clinical reason. Those who have studied testosterone therapy in women strongly advise against the use of testosterone pellets in women, which are injected under the skin, provide too much testosterone, and elevate testosterone levels far beyond the physiologic normal range. This leads to undesired side effects up to and including deepening of the voice, male pattern baldness, excess facial hair growth, and enlargement of the clitoris. Physiologic doses may be achieved using topical testosterone gel in those individuals who meet criteria for supplementation. If this is something you’re wondering about, it deserves its own careful conversation at your visit.
Most women come to me asking about hot flashes, and most leave with a different understanding of what’s at stake. Hormone therapy addresses the surface symptoms: the night sweats, the vaginal dryness, the disrupted sleep. But when started at the right time, it also works at the level of the body’s long-term systems: the cardiovascular system, the skeleton, the brain. That is what makes it preventive medicine, and it is why timing matters as much as the decision to start at all.
Hormone therapy is the most effective treatment available for vasomotor symptoms (the medical term for hot flashes and night sweats), and for women with moderate to severe symptoms, the difference is often dramatic. Women who have gone months without a full night’s sleep before starting treatment may start seeing improvements within weeks of beginning hormone therapy.
This condition includes vaginal dryness, discomfort or pain during sex, urinary urgency, and a higher susceptibility to urinary tract infections. It affects roughly half of postmenopausal women,5 tends to worsen without treatment, and responds well to both systemic and local vaginal estrogen. If sex has become painful or you’ve had more UTIs than usual, this is worth bringing up directly.
Estrogen is central to maintaining bone density. The perimenopausal transition (the years just before and after menopause) is when bone loss accelerates most rapidly, and women can lose up to 20 percent of bone density in the first five to seven years after menopause.4 Hormone therapy started during or shortly after that window preserves bone and reduces fracture risk, and for older women, those fractures carry real consequences, including disability and mortality. Protecting bone density during the perimenopausal years is one of the most evidence-based preventive investments a woman can make.
When hormone therapy is started within ten years of menopause onset, or before age 60, research consistently links it to cardiovascular protection. Estrogen has direct protective effects on blood vessels, and those effects begin to diminish the longer therapy is delayed. Clinicians who specialize in menopause medicine call this the “critical window,” and the evidence behind it is strong.
The cardiovascular advantage is clearest when therapy begins within that window. For women who start estrogen a decade or more past menopause, the picture shifts, because the blood vessels have already changed in ways that alter the risk-benefit balance.
Dementia has many causes and variables, and we are still trying to understand the role estrogen deficiency plays in the development of dementia. Stay tuned over the next few years for more data to guide us.
Better sleep follows from fewer night sweats, and mood and energy often improve from there. Persistent fatigue, one of the most common and underrecognized symptoms of the menopausal transition, frequently improves as well.
Estrogen has direct effects on serotonin and other neurotransmitters, and many women who have been managing anxiety or depression during this transition find that their symptoms become more manageable on hormone therapy.
Brain fog (difficulty concentrating, losing words mid-sentence) has a hormonal component that often responds to treatment. Women frequently notice these shifts within the first few weeks of starting.
In 2002, the Women’s Health Initiative published findings linking hormone therapy to increased risks of breast cancer, heart disease, stroke, and blood clots.7 Physicians across the country stopped prescribing it almost overnight. Women stopped asking.
The findings were real, and specific to the population studied. The study primarily enrolled older postmenopausal women (average age 63), many of whom were obese or had existing cardiovascular risk factors, and many of whom were more than a decade past menopause. The formulations used were oral conjugated equine estrogen combined with a synthetic progestogen, not the transdermal or lower-dose options in common use today. The risks identified were real for that specific population, in those specific formulations, in that specific context; then the warnings were applied universally, to all hormone therapy, for all women.
The FDA’s February 2026 label changes were a formal correction of that overcorrection.2 The agency now states that the earlier cardiovascular, breast cancer, and dementia warnings applied to systemic hormone therapy were misleading when used across the board.
Breast cancer was the headline fear that drove women and physicians away from hormone therapy after 2002. It deserves a direct answer.
The WHI finding that linked hormone therapy to increased breast cancer risk was specific to one formulation: oral conjugated equine estrogen combined with medroxyprogesterone acetate, a synthetic progestogen. That combination, used long-term in an older population, showed a small increased risk. Estrogen alone, for women who have had a hysterectomy, carries no increased breast cancer risk and some analyses associate it with reduced risk.
For combined therapy, a small increased risk does emerge with long-term use, less than one additional case per 1,000 women per year in absolute terms. That risk appears tied primarily to synthetic progestogens. Micronized progesterone, the bioidentical form used in many modern regimens, shows a more favorable profile in the available data,8 and current research continues to refine our understanding. A prospective analysis published in the Journal of the National Cancer Institute in December 2025 found that among women with BRCA1 or BRCA2 mutations, those who used hormone therapy had fewer breast cancer diagnoses than those who did not.
For women with a personal history of breast cancer, hormone therapy is not automatically off the table. The answer depends on the cancer type, its hormone-receptor status, and how it was treated. This requires individual assessment and, in most cases, coordination between the prescriber (primary care doctor/gynecologist) and your oncologist.
For healthy women under 60 who are within ten years of menopause onset, the benefits of hormone therapy outweigh the risks.6 This is the clearest, most current guidance in the field, and one I apply directly in my practice.
For women who are over 60 but still within ten years of menopause, there may still be real value in starting hormone therapy, but the risks require careful weighing. Risks escalate progressively with age — particularly for cardiovascular disease, stroke, venous thromboembolism, and dementia. The evidence is strongest for women aged 70+, where HT is now broadly discouraged, while the 60–69 age group occupies a more nuanced “proceed with caution” zone.
Given that cardiovascular risk increases in this age group, before starting estrogen therapy in a patient over 60, I want cholesterol well-controlled and blood pressure managed. Once hormone therapy is established and tolerated well, it can often be continued for quite a long time. A prolonged estrogen gap, not age alone, is what reduces the overall benefit.
Women who are many years past menopause with no current symptoms present a different picture, and starting hormone therapy in that group requires a more cautious conversation.
Continuation of HRT after age 60 (for women who started before age 60) is different and should be individualized based on personal risk factors. Many women may ultimately benefit from somewhat longer term HRT, but there is always going to be a small risk associated with use.
Hormone therapy isn’t right for every woman. Those with a personal history of blood clots, certain estrogen-sensitive cancers, stroke, or poorly controlled cardiovascular disease need an individual assessment before starting. These are conversations worth having with a physician who knows your full history.
The most common side effects when starting hormone therapy are breast tenderness, mild nausea, and irregular spotting or breakthrough bleeding. These typically resolve within the first two to three months as the body adjusts.
One thing I want to address directly: hormone therapy does not cause weight gain. It’s one of the most persistent myths in menopause medicine, and the evidence consistently tells a different story. The weight changes many women notice during the menopause transition are driven by age-related metabolic shifts, decreased muscle mass, and changes in sleep and activity. Managing menopausal symptoms effectively may actually make it easier to sleep well, exercise consistently, and maintain a healthy weight.
If you experience heavy or prolonged bleeding, persistent breast changes, or anything else that feels off after starting hormone therapy, please reach out to your physician. These are worth a conversation.
“Bioidentical” is a word that gets used in very different ways, and it’s worth separating the two.
“Bioidentical” simply means the hormone’s molecular structure matches what your body naturally produces. FDA-approved versions include estradiol (available as patches, gels, sprays, and pills) and micronized progesterone, both manufactured to consistent, verified standards with known purity and dosing and a well-established safety record.
Compounded bioidentical hormones are a different matter. These are custom preparations made by compounding pharmacies, most commonly pellets implanted under the skin or troches (dissolvable lozenges). The Menopause Society has raised specific concerns about these products because they are not regulated by the FDA, their dosing is inconsistent from batch to batch, and there is no long-term safety data comparable to what exists for approved formulations. They’re often marketed as more natural or personalized, but the safety unknowns are real.
If bioidentical hormones interest you, FDA-approved options provide the same molecular match without the regulatory unknowns.
The old “lowest dose, shortest time” guidance has shifted. That recommendation came directly from the post-WHI overcorrection, and it no longer reflects the current evidence.
There is no universal stop date for hormone therapy. The right duration depends on why you’re taking it, what your symptoms are, your individual risk profile, and how you’re doing over time. My practice is to revisit the decision to continue hormone therapy by reviewing symptoms, risk factors, and overall health together, rather than setting an arbitrary cutoff.
Some women stay on hormone therapy for many years and others choose to stop earlier. That decision belongs to you and your doctor.
For women under 60 or within ten years of menopause onset who are experiencing hot flashes, night sweats, GSM, disrupted sleep, fatigue, brain fog, anxiety, or depression, the case for hormone therapy is clear. In addition, women who went through surgical menopause due to removal of the ovaries often experience more abrupt and pronounced symptoms and have a strong clinical case for hormonal support.
Women with a personal or strong family history of hormone-sensitive cancers, a history of blood clots, uncontrolled hypertension, or active cardiovascular disease need a thorough individual assessment before starting hormone therapy. I’m glad to have that conversation if you’re not sure where you fall.
Non-hormonal options exist and have improved. The most recently FDA-approved treatment for hot flashes is elinzanetant, approved in October 2025,11 a non-hormonal medication that targets the temperature-regulation pathway in the brain. SSRIs, SNRIs, gabapentin, and clonidine are established alternatives for vasomotor symptoms. Non-hormonal vaginal moisturizers and lubricants address GSM symptoms, though they work differently than local estrogen. They are real options for women who need them.
The quality of your menopause care depends on who you’re working with. I am a board-certified internist and a certified menopause practitioner through the Menopause Society (MSCP),13 and that combination matters more than either credential alone. The MSCP reflects specialized, current training in menopause medicine. The internist piece means that when we talk about hormone therapy in my practice, the conversation doesn’t stop at symptoms. Instead, we do a comprehensive review of your medical and family history, and your individual risk factors so we can create a personalized plan tailored to your specific needs.
If you’ve been told hormone therapy isn’t an option, or the conversation has never come up, it may be time for a visit with someone who has current training in this area. The evidence has changed, and your care should reflect that.
Leading the way in women's healthcare is renowned board-certified internal medicine doctor Dr. Eileen West. She has over 20 years of experience and is recognized for her expertise in menopause, osteoporosis, and cardiovascular disease prevention. Her excellence-driven compassionate approach, which is associated with the American College of Physicians, improves the lives of her patients by putting a strong emphasis on their overall well-being.
Location: Fairfax, Virginia
Areas of Expertise: Women's Health, Menopause Management, Cardiovascular Disease Prevention, Osteoporosis Diagnosis and Treatment.
Join our Email Newsletter to get the latest and greatest tips on ways to maximize your health, invitations to educational events, and other practice news!
By submitting this form, you are consenting to receive marketing emails from Eileen West, MD and Associates.
